cdaa has been researched along with Non-alcoholic Fatty Liver Disease in 9 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 9 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Akahane, T; Enomoto, M; Fujimoto, Y; Fujinaga, Y; Kaji, K; Kawaratani, H; Murata, K; Namisaki, T; Nishimura, N; Takaya, H; Takeda, S; Tsuji, Y; Yoshiji, H | 1 |
| Afonso, MB; Amorim, R; Castro, RE; Gautheron, J; Islam, T; Jéru, I; Lenoir, V; Magusto, J; Oliveira, PJ; Prip-Buus, C; Ratziu, V; Rodrigues, CMP; Silva, LC; Simões, RF; Teixeira, J; Vigouroux, C; Wendum, D | 1 |
| Fábián, A; Ferdinandy, P; Gergely, TG; Kovács, A; Kovács, T; Kucsera, D; Merkely, B; Radovits, T; Ruppert, M; Sayour, NV; Tóth, VE; Varga, ZV | 1 |
| Lv, J; Lv, Z; Yu, M; Zang, X; Zhang, J; Zhang, Y | 1 |
| Feldstein, AE; Kaufmann, B; Kim, AD; Kim, SE; Kui, L; Leszczynska, A | 1 |
| Afonso, MB; Alonso, C; Andersen, JB; Arretxe, E; Banales, JM; Bujanda, L; Castro, RE; Eizaguirre, E; Gaspar, MM; Islam, T; Izquierdo-Sanchez, L; Jimenez-Agüero, R; Lewinska, M; O'Rourke, CJ; Pareja, MJ; Prip-Buus, C; Rodrigues, CMP; Rodrigues, PM; Santos-Laso, Á; Simão, AL | 1 |
| Abe, A; Miyajima, K; Nakae, D; Nakane, S; Suzuki-Kemuriyama, N; Yuki, M | 1 |
| Brigstock, DR; Chen, R; Kemper, S; Li, X | 1 |
| Hu, P; Peng, M; Ren, H; Sun, Z; Xiang, H; Xiao, J; Xu, J | 1 |
9 other study(ies) available for cdaa and Non-alcoholic Fatty Liver Disease
| Article | Year |
|---|---|
Rifaximin and lubiprostone mitigate liver fibrosis development by repairing gut barrier function in diet-induced rat steatohepatitis.
Topics: Acetamides; Amino Acids; Animals; Caco-2 Cells; Chloride Channels; Choline; Diet; Humans; Lipopolysaccharides; Liver; Liver Cirrhosis; Lubiprostone; Neuraminidase; Non-alcoholic Fatty Liver Disease; Pregnane X Receptor; Rats; Rats, Inbred F344; Rifaximin; Tight Junction Proteins; Toll-Like Receptor 4 | 2022 |
RIPK3 dampens mitochondrial bioenergetics and lipid droplet dynamics in metabolic liver disease.
Topics: Animals; Energy Metabolism; Hepatocytes; Humans; Lipid Droplets; Lipodystrophy, Familial Partial; Liver; Mice; Mitochondria; Non-alcoholic Fatty Liver Disease; Receptor-Interacting Protein Serine-Threonine Kinases | 2023 |
IL-1β neutralization prevents diastolic dysfunction development, but lacks hepatoprotective effect in an aged mouse model of NASH.
Topics: Animals; Disease Models, Animal; Fibrosis; Interleukin-1beta; Liver; Liver Cirrhosis; Male; Mice; Mice, Inbred C57BL; Non-alcoholic Fatty Liver Disease | 2023 |
Changes in Lipidomics, Metabolomics, and the Gut Microbiota in CDAA-Induced NAFLD Mice after Polyene Phosphatidylcholine Treatment.
Topics: Animals; Gastrointestinal Microbiome; Lipidomics; Liver; Mice; Mice, Inbred C57BL; Non-alcoholic Fatty Liver Disease; Phosphatidylcholines | 2023 |
Myeloid-specific deletion of chitinase-3-like 1 protein ameliorates murine diet-induced steatohepatitis progression.
Topics: Animals; Chitinases; Diet, High-Fat; Disease Models, Animal; Humans; Interleukin-13 Receptor alpha2 Subunit; Liver; Liver Cirrhosis; Mice; Mice, Inbred C57BL; Mice, Knockout; Non-alcoholic Fatty Liver Disease | 2023 |
miR-21-5p promotes NASH-related hepatocarcinogenesis.
Topics: Animals; Carcinogenesis; Carcinoma, Hepatocellular; Choline; Liver; Liver Neoplasms; Mice; MicroRNAs; Non-alcoholic Fatty Liver Disease; Obesity; PPAR alpha | 2023 |
Nonalcoholic steatohepatitis-associated hepatocarcinogenesis in mice fed a modified choline-deficient, methionine-lowered, L-amino acid-defined diet and the role of signal changes.
Topics: Amino Acids; Animals; Carcinoma, Hepatocellular; Cell Transformation, Neoplastic; Choline; Choline Deficiency; Diet, High-Fat; Disease Models, Animal; Fibrosis; Interleukin-8; Liver; Liver Cirrhosis; Liver Neoplasms; Methionine; Mice; Mice, Inbred C57BL; Non-alcoholic Fatty Liver Disease | 2023 |
Production, Exacerbating Effect, and EV-Mediated Transcription of Hepatic CCN2 in NASH: Implications for Diagnosis and Therapy of NASH Fibrosis.
Topics: Animals; Animals, Genetically Modified; Fibrosis; Humans; Mice; Non-alcoholic Fatty Liver Disease | 2023 |
GW9662 ameliorates nonalcoholic steatohepatitis by inhibiting the PPARγ/CD36 pathway and altering the gut microbiota.
Topics: Animals; Diet, High-Fat; Gastrointestinal Microbiome; Liver; Mice; Mice, Inbred C57BL; Non-alcoholic Fatty Liver Disease; PPAR gamma; RNA, Ribosomal, 16S | 2023 |